Skip to main content

FDA Approvals

FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020

FDA News: August 2020

Tumor-Infiltrating Lymphocyte Therapy Induces Responses Across Wide Range of Patients with Advanced Melanoma

Wayne Kuznar

The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer

Wayne Kuznar

Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors

Chase Doyle

Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma

FDA Approvals, Lung Cancer, Oncology

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Oncology

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Prostate Cancer

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

Page 16 of 53
Results 151 - 160 of 522